Vriens et al. identified that by inhibiting SCD in breast cancer cells (not endocrine resistant), FADS2 compensates by producing the alternative FA sapienate, and FADS2 inhibition could reverse this process [30]. This evidence concerns the gene FADS2 and breast carcinoma.